Kornimate/medical-research-clean huggingface dataset:
the adverse drug reaction (adre) profile for polypharmacy

Conditions: Polypharmacy

Summary: polypharmacy, the use of multiple or inappropriate medications, has the potential to harm older adults by causing cognitive impairment, falls, and hospitalisations. the nurse-led intervention (the adre profile) to review mental health medicines has demonstrated improved care quality by: identifying serious adverse drug reactions (adrs); reducing prescription of mental health medicines; reducing the prevalence of pain and nausea; and, increasing non-urgent national health service (nhs) contacts. the investigators will develop adre to encompass medicines commonly prescribed in primary care and evaluate intervention implementation in care homes in aneurin bevan university health board.

the investigators will introduce medicines' monitoring using the padre profile into up to 7 care homes, each with up to 26 residents prescribed \>4 medicines (estimated \~90% residents). each home will identify a nurse lead and a deputy. nurses will be asked to administer the padre profile with all patients prescribed \>4 medicines. barriers, facilitators, and feasibility of the profile will be explored. this will identify how, in which contexts medicines' monitoring can be integrated into routine care, relate the profile to improved processes and outcomes of care, and inform implementation strategies (see logic model in cited papers). data collection: * record review before and after each of 3 administrations of the intervention to identify clinical and prescription changes. narrative accounts of problems causing moderate or severe harm will be prepared. * serial interviews and debriefs with nurses: three per nurse. * stakeholder interviews with patients, participating pharmacists and prescribers for an overview of implementation.

Eligibility criteria:
inclusion criteria: * • resident at the care home and expected to continue to live there for 1 year * currently taking \>3 prescribed medicines daily * willing and able to give informed, signed consent themselves, or where capacity is lacking, a consultee is willing to give advice and assent to the resident participating. exclusion criteria: * age \<18 * prescribed \<4 medicines daily; * receiving active palliative care * not well enough to participate, as screened by their nurses

Keywords: medicines management adverse drug reaction care homes nurses
design and evaluation the effects of kinect-based computer games for u/e training in chronic stroke patients

Conditions: Stroke

Summary: the aims of this study are to (i) develop exergames by using kinect system for training ue function in patient with stroke; and (ii) to test the game's feasibility and effects in a group of patient with chronic stroke.

exercise based computer games can facilitate high volume complex task practice, enhance feedback of movement and increase motivation of participants. those effects are difficult to achieve with standard rehabilitation therapy. the kinect system is a camera-based controller which a player can use to directly control a game through body movement without the need for handheld controllers. using kinect to capture movement is a feasible way to help patients who have difficulties to hold controllers to play exergames. scratch 2.0 is a programming language for kids from the mit media laboratory. it is easy to use for game designing. kinect2scratch allows data from the microsoft kinect controller to be sent to scratch, this means that game programs can be designed with motion control. the aims of this study were to i) develop exergames by using scratch and kinect system for training upper extremity function in patient with stroke; and ii) to test the game's feasibility and effects in a group of patient with chronic stroke. this program will be done within two years. during the first year, investigators will design several exergames which are suitable for training upper extremity function in patient with stroke. investigators will have several experts meetings, involved by physiatrists, occupational therapists and engineers to design the game. when a prototype game is created, investigators will invite two to four patients with stroke to pilot test the game. the game design will be completed till patients and therapists satisfy the design. during the 2nd year, investigators will test the feasibility and effects of the exergames by doing a pilot randomized control trial. investigators will recruit 60 patients with chronic stroke who are admitted to a rehabilitation ward for outpatient rehabilitation, and will randomize participants to experiment or control group. all participants will receive pt and ot training as routine. the additional intervention either exergames or conventional ot will be delivered for 8 weeks with 3 training sessions/week of up to 30 minutes.

Eligibility criteria:
inclusion criteria: * first ever ischemic or hemorrhagic stroke or former stroke without any significant residual motor impairment * 3 months post stroke * impaired arm motor function at brunnstrom stage 3-5 * age 18 years or older exclusion criteria: * severe cognitive impairment defined as \< 20 on mini mental state examination * visual disorders or neglect limiting the ability to comply with treatment regimen * orthopedic problem or other neurological diagnosis that makes the ue dysfunction.

Keywords: stroke kinect rehabilitation upper limbs
structured information during the intensive care unit stay

Conditions: Anxiety

Summary: the purpose of this study is to test whether a structured information program at the beginning of the icu-stay is effective to reduce icu related anxiety and discomfort.

the trial is designed as a prospective multicenter randomized controlled trial including an intervention and a control group. the control group receives an unspecific conversation. the intervention group receives a standardized information program with specific procedural, sensory and coping information about the icu. anxiety will be measured with a vas during icu stay and with a questionnaire after icu discharge.

Eligibility criteria:
inclusion criteria: * elective open heart or abdominal surgery including scheduled icu stay * heart or abdominal surgery or internal patients with non-scheduled icu stay * informed consent exclusion criteria: * reduced sensual perception * cognitive impairment * not able to answer a questionnaire (e.g. illiterate) * lying in the same room with another patient already included

Keywords: information programme anxiety reduction multicenter trial intensive care critical care
validation of the concept of the autoantibodies directed against the neuropeptides involved in food intake regulation on the incidental cases of eating disorders

Conditions: Eating Disorder

Summary: this study should lead to the validation of the concept of the autoac directed against the neuropeptides involved in food intake regulation.

eating disorders are a public health issue. it has been recently reported the importance of immune system modifications in eating disorders physiopathology, involving autoantibodies directed against neuropeptides regulating food intake. a recent study of laboratory inserm 1073 showed the existence of an intestinal bacterial protein exhibiting structural similarities with α-msh: clpb. the autoac directed against the latter also react with α-msh because of these similarity of structures, thus leading to a potential digestive origin of these autoac. to consolidate this new etiopathogenic assumption, a large clinical study is necessary with analysis of patients autoac profiles. a monocentric study with inclusion of 240 patients over 2 years and 80 healthy volunteers is proposed. this study should lead to the validation of the concept of the autoac directed against the neuropeptides involved in food intake regulation. nutritional modulations (probiotic, amino-acid...) could constitute an interesting therapeutic perspective in the future.

Eligibility criteria:
inclusion criteria: patients with eating disorders 1. 18 years and older 2. first clinical visit in nutrition department of chu de rouen for eating disorders 3. anorexia nervosa, hyperphagia or bulimia according to the classification dsm-v 4. social security affiliation 5. patient who signed the mec approved informed consent volunteers 1. 18 years to 60 years 2. body mass index ≥ 18,5 kg/m2 and ≤ 24,9 kg/m2 3. negative scoff test 4. no active and history of eating disorders 5. social security affiliation 6. volunteer who signed the mec approved informed consent exclusion criteria: patients with eating disorders 1. no anorexia nervosa, hyperphagia or bulimia according to the classification dsm-v 2. adults under legal protection or under safeguard of justice or administrative decision 3. pregnancy volunteers 1. active or history of eating disorder 2. adults under legal protection or under safeguard of justice or administrative decision 3. pregnancy

Keywords: autoantibodies (autoac) circulating neuropeptides (ghrelin, l'α-msh) potential digestive origin
green banana peel extract for stasis dermatitis treatment

Conditions: Stasis Dermatitis

Summary: to develop and evaluate a pharmaceutical formula based on green banana peel extract for the treatment of stasis dermatitis.

objective: to develop and evaluate a pharmaceutical formula based on green banana peel extract for the treatment of stasis dermatitis. methods: it will be a clinical, interventional, longitudinal study, random sampling, sample will have 20 patients divided into two groups. in the control group, a moisturizing cream with spf 30 sunscreen plus a pharmaceutical formulation without green banana peel extract will be used, and in the study group, in addition to the spf 30 sunscreen, a pharmaceutical formulation containing green banana peel extract will be used. patients will undergo treatment for 90 days, applying the formulation twice a day, evaluated every 45 days through clinical, photographic and chromatic palette evaluation.

Eligibility criteria:
inclusion criteria: * patients with stasis dermatitis. * patients aged 18 years or over and 60 years or less. * patients who agree to participate in the study. - exclusion criteria: * patients who have other types of hyperchromia in the legs. * patients known to have an allergic reaction to bananas. * patients who give up, for any reason, to continue treatment.

Keywords: stasis dermatitis hyperpigmentation banana skin musa sapientum
fmt for post-infectious ibs

Conditions: Irritable Bowel Syndrome

Summary: considering that pi-ibs is brought on by infection and gut microbiota may be associated with the onset of symptoms, the modification of altered gut microbiota with nonabsorbable antibiotics such as rifaximin-α or probiotics is often employed as first-stage treatment. research in recent years has also shown the potential benefits of fecal microbiota transplantation (fmt) for ibs, which is the replacement of a sick recipient's gut microbiota with fecal material from a healthy donor. even though the only officially approved indication for fmt at this time is recurrent clostridium difficile infection, the effectiveness of fmt is nevertheless being studied for the treatment of other gastrointestinal and non-gastrointestinal pathologies including ibs. to date, several controlled and uncontrolled studies have been conducted to study the effectiveness of fmt for ibs, and most of them have demonstrated positive results. the investigators have not come across studies devoted to the study of the effectiveness of fmt in patients with pi-ibs in the available literature. so, the aim of the current study was to conduct single-centre, randomized clinical trial to assess the safety, clinical and microbiological efficacy of fmt in patients with pi-ibs.


Eligibility criteria:
inclusion criteria * age 18-65 years * pi-ibs diagnosis in accordance with the rome iv criteria * moderate-severe disease activity (as determined by an ibs-symptom severity score ≥175) * normal appearing colon on colonoscopy with biopsy that did not reveal pathology * signed inform consent. exclusion criteria: * systemic disease, immunodeficiency, or previous treatment with immunomodulators; * pregnant or breastfeeding; * previous surgery on the abdominal cavity, with the exception of appendectomy, cholecystectomy, caesarean section and hysterectomy; * severe current disease (hepatic, renal, respiratory, or cardiovascular); * probiotic or antibiotic use within 8 weeks prior to study initiation; * any condition or circumstance that would, in the opinion of the investigator, prevent completion of the study or interfere with analysis of study results.

Keywords: irritable bowel syndrome fecal microbiota transplantation postinfectious irritable bowel syndrome
discoloration of endosequence and mineral trioxde aggregate in revascularization of necrotic immature permanent teeth

Conditions: Pulp Necrosis

Summary: the objective of this study is to evaluate post operative pain after using endosequence versus mineral trioxide aggregate as coronal plug material in revascularization of non vital immature anterior teeth

the treatment of immature young permanent anterior teeth is challenging because in addition of the need of elimination of bacterial infection; the lack of natural apical constriction against which a suitable filling material can be placed is considered the main problem. in the past many different treatments have been proposed for immature permanent teeth with necrotic pulps such as:custom fitting of filling materials like gutta percha, periapical surgeries, apexification. the disadvantages of these treatments are: the compromised crown/root ratio, possibility of vertical fracture. pulp revascularization is dependent on the ability of residual pulp and apical and periodontal stem cells to differentiate. these cells have the ability to generate a highly vascularized and rich living tissue. mta was chosen as coronal seal to be placed over the blood clot due its a biocompatibility, bio-inductivity. however, the disadvantages of mta are: discoloration of the coronal dentine when placed in the canal and the difficult handling properties. recently, a new bioceramic material has been introduced to the market, namely, endosequence which is bioactive, has antibacterial activity, less cytotoxic effect and similar antimicrobial properties, maintain color stability of the tooth when compared to mta

Eligibility criteria:
inclusion criteria: * age of patient range from 8-14 y. * patients are free from any systemic diseases that may hinder the normal healing process. * non vital permanent anterior teeth with open apex. * pulp space not needed for post and core for final restoration. * compliant patient/parent. exclusion criteria: * patients having allergy to medicaments and antibiotics necessary to complete the procedure. * tooth with vital pulp or complete root formation. * teeth with internal or external root resorption. * un-cooperative patients
renal fractional flow reserve in renal artery stenting

Conditions: Renal Artery Stenosis; Hypertension

Summary: the purpose of the study is to determine potential utility of renal fractional flow reserve in prognosis predicting after renal stent implantation.


Eligibility criteria:
inclusion criteria: * at least moderate (60% or more) renal artery stenosis with atheromatic appearance in angiography * hypertension defined according to who criteria * age 18-75 years * signed informed consent obtained exclusion criteria: * bilateral renal artery stenosis or significant renal artery stenosis in solitary kidney * contraindications to percutaneous renal angioplasty with stenting * atrophy of the kidney supplied with stenosed artery * other well known secondary reason for hypertension * chronic heart failure nyha ii-iv * significant valvular heart disease qualified for surgery * persistent atrial fibrillation * renal failure with gfr below 30ml/min

Keywords: fractional flow reserve revascularization prognosis hemodynamics hypertension
efficacy and safety study of intravenous to oral solithromycin (cem-101) compared to intravenous to oral moxifloxacin in treatment of patients with community-acquired bacterial pneumonia

Conditions: Community-acquired Bacterial Pneumonia

Summary: this study will evaluate the safety and efficacy of an experimental antibiotic, solithromycin, in the treatment of adult patients with community-acquired pneumonia.

community-acquired bacterial pneumonia (cabp) is an acute infection of the pulmonary parenchyma with symptoms such as fever or hypothermia, chills, rigors, chest pain, and/or dyspnea. the widespread emergence of antibiotic resistant pathogens, including the macrolide-resistant streptococcus pneumoniae, has resulted in a need for new and effective antibiotics that have activity against cabp pathogens. solithromycin is a fourth generation macrolide antibiotic with excellent activity against resistant s. pneumoniae and other key typical and atypical bacterial respiratory pathogens. a completed phase 2 study showed comparable efficacy to levofloxacin in adults with cabp.

Eligibility criteria:
inclusion criteria: * male and female patients ≥ 18 years of age * an acute onset of at least 3 of the following signs and symptoms (new or worsening): 1. cough 2. production of purulent sputum 3. shortness of breath (dyspnea) 4. chest pain due to pneumonia * at least 1 of the following: 1. fever 2. hypothermia 3. presence of pulmonary rales and/or evidence of pulmonary consolidation * port risk class ii, iii, or iv * presence of lobar, multilobar, or patchy parenchymal infiltrate(s) consistent with acute bacterial pneumonia on a pulmonary imaging study * not received any systemic antibiotics during the prior 7 days exclusion criteria: * ventilator-associated pneumonia * known anatomical or pathological bronchial obstruction or a history of bronchiectasis or documented severe chronic obstructive pulmonary disease * hospitalization within 90 days or residence in a long-term care facility within 30 days prior to the onset of symptoms * fungal pneumonia * pneumocystis jiroveci pneumonia * aspiration pneumonia * other non-infectious causes of pulmonary infiltrates * primary or metastatic lung cancer * cystic fibrosis * active or suspected tuberculosis * hiv or myasthenia gravis

Keywords: pneumonia cabp cap macrolide
raltegravir as early therapy in african-americans living with hiv study

Conditions: HIV Infections

Summary: this is a single arm, longitudinal study to examine the safety, tolerability, and pharmacokinetic and metabolic characteristics of raltegravir among 40 african-american, hiv-infected, patients.

purpose: this study will be a single arm, prospective cohort study to examine the safety, efficacy, and pharmacokinetic and metabolic characteristics of raltegravir in african-american men and women. participants: 40 hiv positive, arv treatment-naive, african-american women and men (estimated to be 70% men, 30% women) procedures (methods): subjects will receive raltegravir 400 mg bid along with truvada for 104 weeks.

Eligibility criteria:
inclusion criteria: * hiv-1 infection documented by hiv serology or detectable viral load * self-described as african-american * less than 7 days cumulative of prior hiv therapy * plasma hiv rna pcr equal to or greater than 1000 copies/ml within 90 days prior to study entry * able to provide informed consent * in the opinion of the investigator, able to comply with study medication and procedures * alt (sgpt) \< or equal to 3.0 x uln within 45 days prior to study entry * grf \> 59 as calculated by mdrd within 45 days prior to study entry * all women of reproductive potential (who have not reached menopause or undergone hysterectomy, bilateral oophorectomy, or tubal ligation) must have a negative serum or urine β-hcg pregnancy test performed within 48 hours before entry. all study volunteers must agree not to participate in a conception process (e.g., active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization) and, if participating in sexual activity that could lead to pregnancy, the female study volunteer/male partner must use at least one reliable method of contraception (e.g., condoms, with or without a spermicidal agent; a diaphragm or cervical cap with spermicide; an iud; or hormonal-based contraception), simultaneously while receiving the protocol-specified medication(s) and for 6 weeks after stopping the medication(s). if oral birth control pills, hormone patches, or hormone injections are used for contraception, then a second method of contraception must be used. exclusion criteria: * pregnancy * breastfeeding * prior receipt of raltegravir * any condition which in the opinion of the investigator is likely to interfere with follow-up or ability to take the study medication appropriately

Keywords: hiv african american treatment naïve
behavioral activation - from inpatient to outpatient services

Conditions: Inpatient Facility Diagnoses; Psychiatric Disorders; Depressive Symptoms

Summary: the purpose of this study is to compare the effectiveness of behavioral activation and supportive therapy added to the standard acute psychiatric inpatient care. therapy starts during inpatient care and can continue in an outpatient facility if the patients are discharged before 12 sessions has been completed.

psychiatric inpatient care is reserved for individuals with the most acute mental health problems. the period after discharge is associated with increased risk for relapse, non-adherence and suicide. delivering high quality psychosocial interventions during and after acute psychiatric inpatient care is known to be a difficult challenge. this study will investigate the effectiveness of adding either behavioral activation or supportive therapy to the standard acute psychiatric inpatient care. subjects with different psychiatric diagnoses and elevated depressive symptoms are assessed and randomized after admission. therapists from the nearest outpatient facility initiate 12 sessions of behavioral activation or supportive therapy as soon as possible. the 12 sessions are delivered twice weekly at the inpatient unit or at the outpatient facility, depending on whether the patient is admitted or discharged. treatment as usual interventions(medications, nursing etc.) are not manipulated in the study. the main assessment points are pre-, post, 6 months follow-up and 12 months follow-up. the main outcome measure and some process measures are also administered at session 3, 6 and 9.

Eligibility criteria:
inclusion criteria: * admitted into one of four acute psychiatric inpatient units in dalarna * madrs-s 20 and above at acute admission and and after 2-3 days on the ward * psychiatric disorder according to m.i.n.i (sheehan et al., 1998) * read and speak swedish exclusion criteria: * acute psychotic symptoms * acute manic symptoms * confusion * primary eating disorder * primary alcohol or substance abuse disorder * self rated score on audit (saunders et al., 1993)of 20 or greater * mental retardation

Keywords: acute inpatient psychiatry continuity of care behavioral activation depression